Brain-sensing synNotch-CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models.

A brain-restricted synNotch CAR T circuit targeting diffuse midline glioma achieved durable tumor clearance and extended survival in multiple preclinical DMG models, including an immunocompetent system.

• Why it matters: DMG has limited options and poor prognosis, while CAR T success depends on improving CNS infiltration/persistence and minimizing on-target/off-tumor neurotoxicity.
• What they did: The authors engineered a BCAN synNotch circuit that induced CAR expression against EphA2 or IL-13Rα2 (B-SYNC) and tested intravenous or intracerebroventricular delivery in immunodeficient DMG models, plus an alternative BCAN-primed B7-H3 or IL-13Rα2 circuit (B-SYNC-B/I).
• The result: Intracerebroventricular delivery triggered fatal neurotoxicity in immunodeficient settings due to low-level B7-H3 in nontumor CNS, but in an immunocompetent syngeneic DMG model, murinized BCAN-gated B7-H3 CAR T cells cleared tumors, resisted rechallenge, and showed no detectable neurotoxicity.